ICH Q1A(R2) Stability Testing Conditions

ICH Q1A(R2) defines a set of standardised storage conditions under which stability data must be generated, reflecting the range of climatic conditions...

ICH Q1A(R2) defines a set of standardised storage conditions under which stability data must be generated, reflecting the range of climatic conditions encountered across the major global regulatory regions. Long-term testing, conducted at 25 degrees Celsius plus or minus 2 degrees and 60 per cent relative humidity plus or minus 5 per cent, corresponding to Climatic Zones I and II, is maintained for a minimum of twelve months at the time of regulatory submission, with data collection ideally continuing to 24 or 36 months to confirm the proposed shelf-life; this condition is intended to reflect real-time storage and forms the primary basis for the labelled expiry period.

An intermediate condition, 30 degrees Celsius plus or minus 2 degrees and 65 per cent relative humidity plus or minus 5 per cent, corresponding to Climatic Zones III and IVa, is maintained for a minimum of twelve months and is of particular relevance to regulatory submissions in India and other Zone IVb territories, where this condition may substitute for or supplement the standard long-term condition depending on the significance of any change observed under accelerated testing. Accelerated testing, conducted at the more aggressive condition of 40 degrees Celsius plus or minus 2 degrees and 75 per cent relative humidity plus or minus 5 per cent, is maintained for a minimum of six months and serves to predict long-term stability performance and to rapidly detect degradation pathways that might take years to manifest under real-time storage conditions, allowing formulation risks to be identified and addressed early in development.

Photostability testing, governed by the companion guideline ICH Q1B, exposes the drug substance and product to a defined quantity of both visible and ultraviolet light — conventionally not less than 1.2 million lux-hours of visible illumination together with an integrated near-ultraviolet energy of not less than 200 watt-hours per square metre — as a single confirmatory exposure, informing packaging decisions such as the need for light-protective primary containers or secondary cartons for photolabile compounds.

For products requiring cold-chain storage, such as many biologics and vaccines, refrigerated stability testing is conducted at 5 degrees Celsius plus or minus 3 degrees for long-term evaluation, typically for twelve months, supplemented by accelerated testing at 25 degrees Celsius to stress-test the formulation's tolerance of transient excursions from labelled storage conditions during distribution. Frozen products, including certain plasma-derived and biological preparations, are evaluated at minus 20 degrees Celsius plus or minus 5 degrees for a minimum of twelve months. Selection of the appropriate combination of these conditions for a given development programme depends on the dosage form, the intended storage recommendation, and the specific climatic zones in which regulatory approval is being sought.